Vaxcyte, a preclinical biotech developing next-generation pneumococcal vaccines, raised $250 million by offering 15.6 million shares at $16, the high end of the range of $14 to $16. The company offered 1.6 million more shares than anticipated. At pricing, the...read more
Three large preclinical biotech IPOs are slated to begin trading on Friday, the most ever in a single week.
Vaxcyte (PCVX) is developing next-generation pneumonia vaccines, a $7 billion market, and expects to begin clinical trials for its...read more
Vaxcyte, a preclinical biotech developing pneumococcal vaccines, announced terms for its IPO on Monday. The Foster City, CA-based company plans to raise $210 million by offering 14 million shares at a price range of $14 to $16. At the midpoint of the...read more
US IPO Weekly Recap: Vroom soars in another 8 IPO week
Eight IPOs and one SPAC entered the public markets this past week led by Vroom (VRM), which popped 118% in ...read more
Vaccine biotech Vaxcyte prices upsized IPO at $16 high end
Vaxcyte, a preclinical biotech developing next-generation pneumococcal vaccines, raised $250 million by offering 15.6 million shares at $16, the high end of the range of $14 to $16. The company offered 1.6 million more shares than anticipated. At pricing, the...read more
No trial, no problem: Biggest week for preclinical biotech IPOs ever
Three large preclinical biotech IPOs are slated to begin trading on Friday, the most ever in a single week. Vaxcyte (PCVX) is developing next-generation pneumonia vaccines, a $7 billion market, and expects to begin clinical trials for its...read more
Preclinical vaccine biotech Vaxcyte sets terms for $210 million IPO
Vaxcyte, a preclinical biotech developing pneumococcal vaccines, announced terms for its IPO on Monday. The Foster City, CA-based company plans to raise $210 million by offering 14 million shares at a price range of $14 to $16. At the midpoint of the...read more